INVESTOR DUE DILIGENCE & ASSET DEVELOPMENT

Make clinical plans financeable

Independent clinical-development judgment for investors, boards and companies preparing to finance or partner an asset.

The problem

A compelling mechanism is not yet an investable development path

Clinical uncertainty, execution risk, time, budget and value-inflection milestones are often described separately. Technical diligence needs one coherent view of what can fail, what can be learned and which capital release is justified.

What we do

Translate clinical risk into underwriteable decisions

Independent mechanism, translational and development-thesis review
Competitive, regulatory, pivotal-design and execution-risk assessment
Clinical risk map with mitigation paths
Development plan, timeline and evidence gates
Use-of-proceeds logic tied to value-inflection milestones
Board-ready and diligence-ready decision packages
Fundraising and partnering readiness tied to the clinical evidence path

CAPITAL DISCIPLINE

Make every euro of runway buy a clearer decision

Boards and investors do not only ask whether the science is promising. They ask how much capital is exposed before the next value-inflection point, what evidence that spend will buy, which assumptions can still be reversed and how delay, redesign or an uninterpretable readout would affect the financing narrative.

Runway to the next decision

Translate timeline and burn into the capital required to reach a decision that can genuinely change asset value.

Use-of-proceeds discipline

Tie spend to evidence, execution and de-risking milestones rather than broad activity categories.

Irreversible spend

Identify which commitments should wait until pivotal assumptions, feasibility and governance have survived challenge.

Valuation narrative

Connect the clinical architecture to what a board, investor or partner can credibly underwrite at the next financing or transaction gate.

Best fit

Use this mandate when capital and evidence must move together

An investor requires independent clinical diligence.
A board must choose between development paths.
A company is preparing to finance, partner or license an asset.
Milestones and use of proceeds are not tied to explicit evidence decisions.
The clinical narrative is stronger than the execution architecture.

WHAT CHANGES AFTER THE ENGAGEMENT

From an asset story to an underwriteable development path

BEFORE

Risk and value were described separately

Clinical uncertainty, execution assumptions, financing needs and value-inflection milestones were not expressed in one decision architecture.

INTERVENTION

Build one diligence narrative

Risk, evidence gaps, mitigations, development gates, timelines and use of proceeds were connected into one board- and investor-readable plan.

WHAT CHANGED

Capital could be discussed against explicit gates

The development case became easier to challenge, finance and partner because the next spend was tied to observable evidence and execution milestones.

OBSERVED CONTEXT

Financing and value-inflection discussions >$50M

Across selected engagements, integrated clinical risk, evidence and mitigation narratives contributed to financing and value-inflection discussions exceeding $50M. This is contextual evidence, not a guarantee of fundraising outcomes.

View more verified case snapshots →

Connect diligence to a governed development path

A decision-grade next step

Turn the asset narrative into a governed evidence path.

Tie capital release to observable progress and explicit decision gates.